Ace Therapeutics Expands Preclinical Hematology CRO Services with Advanced Disease Modeling Platforms

Ace Therapeutics has officially launched a comprehensive suite of integrated preclinical hematology services, specifically designed to accelerate the development of novel therapies for complex blood disorders. By unifying in vitro modeling, in vivo efficacy testing, and specialized biomarker profiling, the organization provides a robust framework that helps pharmaceutical developers overcome significant bottlenecks in translational research. This end-to-end approach ensures that innovators can efficiently advance diverse modalities, including gene therapies, RNA-based treatments, and cell-based interventions.

The company’s expanded portfolio features an extensive collection of in vivo hematologic disease models, including genetically engineered lines, patient-derived xenografts, and chemically induced platforms. These models span multiple species, such as mice, rats, and non-human primates, allowing for highly accurate assessments of sickle cell disease, thalassemia, and bone marrow failure. By integrating these models with cutting-edge 3D hematopoietic culture systems, Ace Therapeutics enables high-throughput, human-relevant mechanistic research that bridges the gap between early discovery and clinical application.

Beyond model development, Ace Therapeutics provides full-spectrum support throughout the drug development lifecycle, including target validation, specialized PK/PD profiling, and rigorous safety toxicology. All workflows adhere to strict quality control standards, ensuring the production of regulatory-ready data. This commitment to scientific excellence empowers biotechnology companies to navigate the complexities of hematologic research with confidence, ultimately speeding the delivery of life-saving treatments to patients suffering from rare and inherited blood conditions.